Potential of pharmacogenetics in treatment of chronic inflammatory diseases - a danish report overview from 2000 - 2024 [0.03%]
药理遗传学在慢性炎症性疾病治疗中的潜力——一份丹麦2000-2024年的报告概述
Trine Andresen,José A G Agúndez,Hela Nazari et al.
Trine Andresen et al.
Given the substantial degree of inter-individual variability in treatment responses in patients with inflammatory bowel disease (IBD), treatment optimization is warranted. We provide an overview of pharmacogenetic variants that can affect t...
A functional ancestry-linked regulatory haplotype influences CYP2D6 expression [0.03%]
一个功能性的亲缘相关性调节单体型影响CYP2D6表达
Michael McCoy
Michael McCoy
Cytochrome P450 (CYP) enzymes metabolize 70-80% of therapeutic agents, yet regulatory variants affecting drug metabolism remain poorly characterized across populations. Although numerous studies have examined coding variants in pharmacogene...
Use of medications with pharmacogenomic guidelines and adverse outcomes in hospitalised older patients: a retrospective cross-sectional study [0.03%]
药物基因指南指导下用药与住院老年患者不良临床结局关系的回顾性横断面研究
Victoria David,Ciarán D McInerney,Justine Tomlinson et al.
Victoria David et al.
This study aimed to assess the prevalence of the use of medications with pharmacogenomic guidelines upon hospital admission in patients aged 65 and over and evaluate its association with adverse outcomes, including length of stay, unplanned...
Pharmacogenomics to optimise psychotropic prescribing: a survey of mental health professionals' perceptions, knowledge, and educational needs [0.03%]
药物基因组学在优化精神活性药物处方中的应用：调查心理健康专业人员的看法、知识和教育需求
Daniele Panconesi,Stephen Murtough,Marius Cotic et al.
Daniele Panconesi et al.
A survey was conducted to determine attitudes, knowledge, and educational needs of mental health professionals regarding pharmacogenomics. We recruited 128 clinicians working in mental health in England, and we assessed their experiences us...
Combined Role of CYP3A4 and CYP3A5 genetic variants in tacrolimus dose-adjusted trough levels: a clinical retrospective study in kidney transplant patients [0.03%]
肾脏移植患者他克莫司调整剂量的血药浓度与CYP3A4和CYP3A5基因多态性的临床相关性研究
Anna Tsironi,Effrosyni Mendrinou,Stavroula Siamoglou et al.
Anna Tsironi et al.
Tacrolimus, a calcineurin inhibitor with a narrow therapeutic index, requires precise dosing to optimize efficacy and minimize adverse effects in kidney transplant recipients. Although CYP3A5 genetic variants influence tacrolimus pharmacoki...
Comparative analysis of point-of-care bedside cyp2c19-testing guided anti-platelet therapy versus conventional therapies for cardiovascular diseases: a systematic review and meta-analysis [0.03%]
基于护理点鸟苷酸环化酶活性床旁CYP2C19基因分型指导的抗血小板治疗与传统疗法治疗心血管疾病的比较分析：系统综述和meta分析
Mohammed Khattab,Mohamed Baguneid,George P Patrinos et al.
Mohammed Khattab et al.
Genetic variation in CYP2C19 is linked to variable efficacy in antiplatelet therapies like clopidogrel. Patients with CYP2C19*2 and *3 loss of function alleles show reduced enzyme function, leading to lower active drug levels and higher ris...
mLeveraging genetic correlations to prioritize drug groups for repurposing in type 2 diabetes [0.03%]
利用遗传相关性优先确定2型糖尿病药物再定位的药物组
Astrid Johannesson Hjelholt,Tahereh Gholipourshahraki,Zhonghao Bai et al.
Astrid Johannesson Hjelholt et al.
Type 2 diabetes (T2D) is a complex, polygenic disease with substantial health impact. Despite extensive genome-wide association studies (GWAS) identifying risk loci, therapeutic translation remains limited. We applied a Bayesian Linear Regr...
Genetic and pharmacokinetic factors associated with imatinib-induced toxicities in gastrointestinal stromal tumors [0.03%]
与胃肠间质瘤伊马替尼诱导的毒性相关的影响遗传和药代动力学因素
Wei Zhuang,Yi Zeng,Xinping Lin et al.
Wei Zhuang et al.
Imatinib is associated with significant toxicities, including myelosuppression, oedema, and hypersensitivity, with considerable interpatient variability. Pharmacokinetic and pharmacogenomic factors contribute, but comprehensive biomarkers a...
Mitochondrial DNA variants and susceptibility to anti-tuberculosis drug-induced liver injury in Korean patients [0.03%]
线粒体DNA变异与韩国结核病患者抗结核药物性肝损伤易感性的关联研究
Vinh Hoa Pham,Sang-Heon Kim,Young-Koo Jee et al.
Vinh Hoa Pham et al.
It has been proposed that mitochondrial DNA variations can affect mitochondrial function, increasing the risk of drug-induced liver injury. This study aims to explore the association between mitochondrial DNA (mtDNA) variants and anti-tuber...
Anna Shteto,Jawad Boulahfa,Adrien Etcheto et al.
Anna Shteto et al.
Predictive safety risk biomarkers for drug-induced liver injury (DILI) are critically needed to enhance patient risk stratification and minimize adverse outcomes. This study aims to identify genomic markers associated with increased mortali...